Integrative review, XIII Paulista Congress of Neurology, May 2021; São Paulo (SP). Efficacy of cannabidiol in improving the quality of life of Parkinson´s Patient; ITPAC-Palmas (TO); 2021

Abstract

Introduction: Parkinson’s disease (PD) is a neurodegenerative disease, caused by an imbalance between the inhibitory action of dopamine and the excitatory action of acetylcholine due to dopamine restriction, characterized by motor and non-motor symptoms. The phytocannabinoid cannabidiol (CBD) may be effective for the treatment of symptoms in PD, offering better quality of life. Objectives: To verify the evidence for the efficacy of cannabidiol in the treatment of patients with PD about the improvement of quality of life. To analyze its applicability in controlling involuntary movements in PD patients. Methods: A search in the databases LILACS, BIREME, SCIELO, SCIENCE, EBSCO, PUBMED, using the bibliographic research method, and by means of integrative review. The descriptor cannabidiol was associated with the words: therapeutic use, parkinsonism, and quality of life. The selection included articles published between 2000 and 2020, in Portuguese, English and German languages. Results: Therapeutic effects of cannabidiol were promising in PD, such as neuroprotective action, reduction of motor symptoms, cognitive and quality of life improvement with few relevant adverse effects. Among the 16 articles, 8 demonstrate an improvement in symptoms and the others cite improvement in psychiatric and cognitive symptoms, thus reflecting that cannabidiol is a promising for quality of life improvement. Conclusion: Although cannabidiol has shown efficacy in the therapy of Parkinson’s patients in clinical and preclinical studies, there is still a need for further studies and investigations on the therapeutic effects of this compound. Thus, cannabidiol may become a first choice treatment for PD, promote patients and families a better living with the disease, and positive reflexes.